A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Not yet recruiting · NCT07833618 · Registry updated 2026-09-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07833618 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Capital Medical University Affiliated Beijing Tiantan Hospital | Beijing | China | 2 |